Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: y2kfree_radical who wrote (55383)	7/19/2000 3:18:38 PM
From: StocksDATsoar	Read Replies (1) \| Respond to of 150070

ragingbull.altavista.com By: glens0 Reply To: None Wednesday, 19 Jul 2000 at 1:05 PM EDT Post # of 582 Some information from dnaprint.com The Opportunity In order to develop novel treatments and medicines for human disease, efforts began about 15 years ago to map and sequence the entire human genome. Several billion dollars has been spent to produce a public database of human genetic information which will be 90% complete by March 2000. This massive project and other privately funded projects which focus on expressed genes, enables the study of human genetic variation because it allows for the identification of SNPs between different donors. Two things are happening here for the first time in human history. Science is learning the precise chromosomal positions where individual human beings differ from one another.(ie. SNP discovery) High-throughput SNP analysis technology is now available and enables unprecedented screening of huge numbers of SNPs against various afflictions and phenotypes. From Schilling et al., Biotechnol. Prog. 1999, 15, 298-295: "(With the close of the human genome project), DNA sequence data now need to be translated into functional information, both in terms of the biochemical function of individual genes, as well as their systematic role in the operation of multigenic functions." Advancement in our understanding of human genetic variation and the development of new technologies by which to analyze this information brings us to the cusp of making Personalized Medicine a reality. The mining of genome information for phenomics value can be likened to a "gold rush". Our proprietary technologies and approaches, combined with newly created "picks" and "shovels", render us well poised to stake our share in this rush. Copyright DNAprint genomics © 2000